Search clinical trials for: Pegylated Liposomal Doxorubicin (PLD)

Total 1216 results

AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (NGR018)

Ovarian Cancer

Italy, United Kingdom
University of Leicester

Unknown

Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer

Gastric Cancer | Esophageal Cancer

United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable Sarcoma

United States
Merck Sharp & Dohme LLC

Terminated

Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)

Breast Neoplasm
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer

Endometrial Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Breast Neoplasm
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Ovarian Neoplasms
WiSP Wissenschaftlicher Service Pharma GmbH
ClinAssess GmbH

Unknown

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (PROVE)

Ovarian Cancer

Germany
Brown University

Unknown

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Imunon

Completed

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Prof Dirk Elling

Completed

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer (LAPADO)

Breast Cancer

Germany
Fudan University

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

China
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Withdrawn

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Multiple Myeloma
Georgetown University
National Cancer Institute (NCI)

Completed

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

Unspecified Adult Solid Tumor, Protocol Specific

United States
Seoul National University Hospital

Unknown

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

High Grade Serous Carcinoma | Ovarian Neoplasm Epithelial

Korea, Republic of
Swiss Group for Clinical Cancer Research

Completed

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Breast Cancer | Palmar-plantar Erythrodysesthesia

Switzerland
Merck Sharp & Dohme LLC

Terminated

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

Breast Neoplasms
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute

Terminated

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Endometrial Cancer

United States
The Netherlands Cancer Institute

Unknown

Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases

Meningeal Carcinomatosis

Netherlands
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Sarcoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Norway
Masonic Cancer Center, University of Minnesota

Completed

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Sarcoma

United States
Merck Sharp & Dohme LLC
Princess Margaret Hospital, Canada

Completed

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Ovarian Neoplasms
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Breast Cancer

Greece
Millennium Pharmaceuticals, Inc.

Withdrawn

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Ovarian Cancer

Italy, Switzerland
SOLTI Breast Cancer Research Group
Schering-Plough

Completed

Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (CAPRICE)

Breast Cancer

Spain
Peking University

Recruiting

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
National Cancer Institute (NCI)

Completed

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Fallopian Tube Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Female Reproductive Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

United States, Australia, Korea, Republic of, Japan, Belgium, Chile, Spain, Italy, Israel
Zhejiang University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; Second Affiliated... and other collaborators

Unknown

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients (ESNDBCP)

Breast Cancer

China
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Ovarian Neoplasms

Belgium, France, Slovakia, Spain, Sweden
M.D. Anderson Cancer Center

Completed

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Solid Tumors

United States
Joseph Tuscano
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

United States
Merck Sharp & Dohme LLC
Essex Pharma GmbH

Completed

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Breast Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
NYU Langone Health
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

Breast Cancer

United States
Peking University People's Hospital
Xijing Hospital; Peking Union Medical College Hospital; Chinese PLA General Hospital and other collaborators

Withdrawn

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma (PDVPSTS)

Toxicity | Overall Survival | Progression-free Survival

China
Novo Nordisk A/S

Completed

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

Cancer | Ovarian Cancer

Germany, France
Johnson & Johnson Pharmaceutical Research & Development...
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Terminated

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Metastatic Breast Cancer

United States
THERAPIM PTY LTD
Novotech (Australia) Pty Limited

Terminated

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Australia
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer

Breast Cancer

United States
Peking University People's Hospital
Hunan Cancer Hospital; Peking University Cancer Hospital & Institute; Peking... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma (ALTER-S001)

Sarcoma

China

Search clinical trials for: Pegylated Liposomal Doxorubicin (PLD)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations